MIRA-55 Shows Strong Oral Bioavailability and Brain Exposure in Preclinical PK
MIRA is trading near its 52-week low of $0.896 (4.9% above the low) on light trading volume (0.3× avg).
Summary
MIRA-55, an oral therapy for chronic inflammatory pain, demonstrated favorable oral bioavailability and reproducible brain and liver distribution in preclinical PK studies. This is the first disclosure of these specific pharmacokinetic results, building on prior preclinical efficacy data where oral MIRA-55 outperformed injected morphine. The data support continued development as an oral treatment, with further tissue exposure and efficacy studies planned. The company, with a market cap near $39M and stock trading near its 52-week low, advances MIRA-55 alongside its lead candidate Ketamir-2, which recently entered Phase 2a planning.
At the time of this announcement, MIRA was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.7M. The 52-week trading range was $0.90 to $2.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.